HIV Treating Drugs may Prevent COVID-19 Infections


While they have not been shown to cure COVID-19 infections in the general population, their efficacy for preventing COVID-19 is unknown.

To explore this further, researchers conducted a multicentre cohort study in six hospitals in le-de-France to assess the effect of long-term use of PIs in patients with HIV on the incidence of COVID-19.

Between May 1, 2020 and May 31, 2021, they enrolled 169 people with HIV who were treated with ART with PI, and 338 patients with HIV who took ART without PI. None of the participants had been previously diagnosed with COVID-19, with an average age of 50 years (48% female; 52% male).

Among participants being treated with PI, more than three-quarters were taking darunavir/ritonavir (131/169; 77%), about 8% were taking atazanavir/ritonavir (14/169), and the rest were taking other treatments. was done with PI (24/). 169; 14%). On average, they had been taking PIs for at least a year.

All patients had routine clinical assessment and screening for COVID-19 during normal HIV follow-up (every 6 months). Modeled to identify potential risk factors associated with COVID-19.

Over one year of follow-up (with few patients for follow-up in both groups) 12% (18/153) of the participants taking a PI and 22% (61/283) in the non-PI group developed COVID-19. contracted COVID-19, evaluated by positive SARS-COV-2 serology at the end of the study, and four patients in the non-PI group were hospitalized with COVID-19.

After adjusting for factors associated with an increased risk of COVID-19, including gender, age, CD4 cell count, number of people living in the household, contact with a positive COVID-19 case.

He also found that Patients in the protease inhibitor group were 70% less likely to be infected with COVID-19 than patients in the non-PI group,

Patients in both groups who were exposed to COVID-19 in the 14 days prior to their consultation were twice as likely to test positive for COVID-19.

While those living with at least three other people in the same household were three times as likely to test positive; And those who lost their sense of taste were six times more likely to get COVID-19.

More studies are needed in randomized trials in larger numbers of patients with and without HIV to confirm these preliminary results. The challenge will be to produce robust data over a limited period of time that may inspire new prevention or therapeutic strategies.

Source: MadeIndia

Stay Connected With Us On Social Media Platforms For Instant Updates Click Here To Connect With Us TeaveterAnd Facebook





Source link

Leave a Comment